Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

IBD-associated pyoderma gangrenosum in the biologic era

The most recent issue of the Alimentary Pharmacology & Therapeutics investigates inflammatory bowel disease-associated pyoderma gangrenosum in the biologic era, the response to therapy.

News image

Pyoderma gangrenosum in inflammatory bowel disease (IBD) is uncommon and therapeutically challenging.

Dr Andrews and colleagues from Australia and colleagues reported that its treatment remains poorly characterized due to limited individual center or practitioner experience.

No large series are reported since 2003, yet inflammatory bowel disease treatment has changed substantially.

The team provided an up-to-date review of the published treatment efficacy of currently available therapies for inflammatory bowel disease-related inflammatory bowel disease in the biologic era.

The researchers performed a systematic review of cases published post-2003 since the broad availability of anti-tumor necrosis factor-alpha therapy.

Cases which did not have coexistent inflammatory bowel disease, were non-English language, of pediatric age or without data on response to therapy were excluded.

The doctors analyzed 60 cases, of which 55% were female, 50% had ulcerative colitis, 45% had Crohn's disease, 5% had inflammatory bowel disease.

In 12%, trauma preceded pyoderma gangrenosum
Alimentary Pharmacology & Therapeutics

At pyoderma gangrenosum diagnosis, 58% had active and only 15% inactive inflammatory bowel disease, with 27% with inflammatory bowel disease activity unspecified.

Predominant sites were lower limb, and peristomally 42% had multiple lesions.

In 12%, trauma preceded pyoderma gangrenosum.

In 42%, new pyoderma gangrenosum appeared whilst on inflammatory bowel disease-specific therapy, whilst 28% were on no therapy, and in 30% inflammatory bowel disease therapy was unspecified.

Of patients on no therapy at pyoderma gangrenosum, 16 healed, 7 with first- and 8 with second-line therapy.

The doctors used in total, 34 out of 60 patients received infliximab, 4 received adalimumab, 2 had both, with 33 responding to one or the other.

There was no correlation of pyoderma gangrenosum duration or size with healing times.

Dr Andrews' team concludes, "Pyoderma gangrenosum appears predominantly during active inflammatory bowel disease and is seen equally in Crohn's disease and ulcerative colitis."

"New pyoderma gangrenosum may be a manifestation of recrudescent inflammatory bowel disease or it follow trauma."

"Anti-TNFa therapy as a first-line agent for pyoderma gangrenosum should be considered, as it appears to be highly effective."

Aliment Pharmacol & Ther 2013: 38(6): 563–572
23 August 2013

Go to top of page Email this page Email this page to a colleague

 03 August 2015

Advanced search
 03 August 2015 
Lack of response to therapy in severe ulcerative colitis
 03 August 2015 
Vaccinations and IBD
 03 August 2015 
Nutritional vs biological therapy in Crohn's
 31 July 2015 
Risk of hepatocellular carcinoma in chronic HCV with diabetes
 31 July 2015 
Prognostic index for hep C-related cirrhosis
 31 July 2015 
Reducing surgical site infection after stoma reversal
 30 July 2015 
Post-colonoscopy colorectal cancer rates
 30 July 2015 
Venous thromboembolism in colorectal surgery
 30 July 2015 
Saccharomyces boulardii for antibiotic-associated diarrhea
 29 July 2015 
Sitafloxacin-based triple therapy for H.pylori
 28 July 2015 
Lifestyle changes after colorectal cancer screening
 27 July 2015 
Fecal microbiota transplantation for severe C. difficile infection
 24 July 2015 
Causes of death in celiac disease
 23 July 2015 
Reduction in H. pylori prevalence
 22 July 2015 
Detection of esophageal eosinophilia and eosinophilic esophagitis
 21 July 2015 

Clinical outcomes for Barrett's esophagus neoplasia

 20 July 2015 
Certolizumab pegol for Crohn's disease
 17 July 2015 
Genetic variation and gastric cancer
 17 July 2015 
Colitis associated with anti-CTLA-4 therapy
 17 July 2015 

Sexual dysfunction after rectal cancer treatment

 16 July 2015 
Lynch syndrome screening by microsatellite instability
 16 July 2015 
Hormones and endometrial cancer in Lynch syndrome
 16 July 2015 
Relapse of IBD after discontinuation of anti-TNF therapy
 15 July 2015 
Risk prediction index for advanced colorectal cancer
 15 July 2015 
Aspergillus niger-derived enzymes
 15 July 2015 
Prophylactic omeprazole improves GI symptoms
 14 July 2015 
Combination therapies for chronic HCV
 14 July 2015 
Interferon- and ribavirin-free treatment regimen for HCV
 14 July 2015 
Cancer surveillance in ulcerative colitis
 13 July 2015 
Colon polyps in chronic inflammatory conditions of the colon
 13 July 2015 
Drugs and occult vs overt upper GI bleeds
 13 July 2015 
Anxiety and depression in functional GI disorders
 10 July 2015 
Daclatasvir in the treatment of chronic HCV
 10 July 2015 
Surveillance intervals to reduce colorectal cancer
 10 July 2015 
Stress and GI symptoms in IBD
 09 July 2015 
Opioid-induced esophageal dysfunction
 09 July 2015 
Marker of response to medical therapy in Crohn's
 09 July 2015 
Predictive factors for metastasis in colorectal cancer
 08 July 2015 

Nucleoside analogue therapy in HBeAg-negative chronic hepatitis B?

 08 July 2015 

Medical education in endoscopy training

 08 July 2015 
Chronic unexplained nausea and vomiting
 07 July 2015 
Anastomotic leak after elective surgery for colonic cancer
 07 July 2015 
Fecal transplantation for ulcerative colitis
 07 July 2015 
Obesity and risk of hepatocellular carcinoma
 06 July 2015 
Fecal microbiota transplantation
 06 July 2015 
Liver Failure–Sequential Organ Failure Scoring System
 06 July 2015 
Future colorectal surgery for metachronous cancers
 03 July 2015 
Tumors with mismatch-repair deficiency
 03 July 2015 
Aptitude of trainees in endoscopic ultrasonography
 03 July 2015 
Extracolonic pathologies in colorectal cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Anastomotic leak and cancer cancer
 02 July 2015 
Health care use by IBD children
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us